💨 Abstract

Indian drugmakers are expected to remain competitive in the U.S. generic drug market despite potential tariffs on pharmaceutical imports proposed by President Trump, according to Dr. Reddy's Managing Director GV Prasad. Trump has suggested tariffs of 25% or more, and the U.S. accounts for about a third of India's pharmaceutical exports, primarily generic versions of popular drugs.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖